SCHEMBL12440410

SCHEMBL12440410

CCOc1ccc(N)cc1C(F)(F)F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.54
GAA P10253 3/20 0.54
KDM4E B2RXH2 3/20 0.54
POLB P06746 3/20 0.50
TSHR P16473 2/20 0.50
GLA P06280 1/20 0.50
RXRA P19793 1/20 0.50
RXRB P28702 1/20 0.50
RXRG P48443 1/20 0.50
CTSS P25774 5/20 0.46
ATM Q13315 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
LMNA P02545 1/20 0.44
CTSK P43235 4/20 0.43
PDE3B Q13370 1/20 0.43
PDE3A Q14432 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
ALDH1A1 P00352 3/20 0.42
MEN1 O00255 2/20 0.42
TP53 P04637 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28390457 0.86 GAA (0.60) MAPTGAAKDM4EPOLBTSHR
SCHEMBL26460476 0.85 GAA (0.53) MAPTGAAKDM4EPOLBTSHR
SCHEMBL2791295 0.84 ALDH1A1 (0.53) MAPTGAAKDM4EPOLBTSHR
SCHEMBL3423050 0.83 S1PR1 (0.56) MAPTGAAKDM4EPOLBTSHR
SCHEMBL8178482 0.83 GLA (0.47) MAPTGAAKDM4EPOLBTSHR
SCHEMBL17208962 0.82 S1PR1 (0.58) MAPTGAAKDM4EPOLBTSHR
SCHEMBL13665315 0.82 S1PR1 (0.58) MAPTGAAKDM4EPOLBTSHR
SCHEMBL12678747 0.81 GAA (0.46) MAPTGAAKDM4EPOLBTSHR
SCHEMBL28801748 0.81 GAA (0.46) MAPTGAAKDM4EPOLBTSHR
SCHEMBL2793455 0.81 GAA (0.46) MAPTGAAKDM4EPOLBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3191449-B1 COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2020-07-01 EP disclosed
US-10294236-B2 Compounds as rearranged during transfection (RET) inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-05-21 US disclosed
US-20180099976-A1 NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-04-12 US disclosed
US-9879021-B2 Compounds as rearranged during transfection (RET) inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-01-30 US disclosed
US-20170298074-A1 NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-10-19 US disclosed
EP-2354134-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF Astellas Pharma Inc. (JP) 2011-08-10 EP disclosed
WO-2010064707-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF アステラス製薬株式会社 (JP) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10294236-B2 Compounds as rearranged during transfection (RET) inhibitors RET, FER, THRB MAPT 1615/4885GAA 4011/4885KDM4E 4347/4885
US-20170298074-A1 NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS RET, FER, THRB MAPT 1673/4885GAA 4363/4885KDM4E 4282/4885
US-20180099976-A1 NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS RET, FER, THRB MAPT 1673/4885GAA 4363/4885KDM4E 4282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.